下调MICA/MICB可改善NKG2DL CAR T细胞在复发或难治性急性髓系白血病或骨髓增生异常肿瘤患者中的细胞持续性和临床活性
两项I期试验评估淋巴细胞清除后单次输注NKG2DL CAR T细胞治疗复发或难治性AML/MDS。DEPLETHINK试验评估CYAD-01(17例),CYCLE-1试验评估下调MICA/B的CYAD-02(12例)。CYAD-02较CYAD-01植入更高、临床活性改善(客观缓解率17% vs 无客观缓解),两者耐受性良好。
要点
- CYAD-02组客观缓解率17%,CYAD-01组无客观缓解。
- 3或4级细胞因子释放综合征发生率CYAD-01组25%、CYAD-02组33.3%。
- CYAD-02植入高于CYAD-01,证实敲低MICA/B可增强CAR T细胞持续性。
核心结论
- 敲低MICA/B可增强CAR T细胞持续性和疗效,同时维持良好的安全性特征,提供原理验证。
研究设计与样本
- 两项I期试验:DEPLETHINK试验(NCT03466320)评估CYAD-01,CYCLE-1试验(NCT04167696)评估CYAD-02,均在类似复发或难治性AML/MDS患者人群中于单次CAR T细胞输注前进行淋巴细胞清除。
- DEPLETHINK试验治疗17例患者,CYCLE-1试验治疗12例患者。
主要发现
- DEPLETHINK试验中3或4级细胞因子释放综合征发生率为25%,CYCLE-1试验中为33.3%。
- CYAD-02较CYAD-01植入更高,临床活性改善:CYAD-02客观缓解率17%,CYAD-01无客观缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The NKG2D receptor binds eight ligands (NKG2DL) overexpressed in a wide range of malignancies, but largely absent on non-neoplastic cells. Initial clinical evaluation of NKG2DL chimeric antigen receptor (CAR) T-cells (CYAD-01) in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic neoplasia (MDS) demonstrated low durability of responses and short cell persistence. Two Phase I trials were initiated to evaluate the effect of lymphodepletion prior to a single CAR T-cell infusion in a similar r/r AML/MDS patient population. The DEPLETHINK trial (NCT03466320) evaluated CYAD-01 while the CYCLE-1 trial (NCT04167696) evaluated a next-generation NKG2DL CAR, CYAD-02, where the two main NKG2D ligands MICA and B are downregulated, to increase CAR T-cell persistence. Seventeen and twelve patients were treated in the DEPLETHINK and CYCLE-1 trials, and confirmed the good tolerability of both products with cytokine release syndrome (CRS) grade 3 or 4 reported in 25% and 33.3% of patients, respectively. CYAD-02 presented an higher engraftment and an improved clinical activity (17% objective response rate) compared to CYAD-01 (no objective response). Altogether, our data provide proof of principle that knock-down of MICA/B can enhance CAR T-cell persistence and efficacy while maintaining a good safety profile.
引用
- Pollyea D, Kerre T, Deeren D, et al. Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia. Leukemia. 2025. PMID: 40954213. doi:10.1038/s41375-025-02767-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。